Charles River Laboratories International stock
Price history
+99.73% over the period1 year: from $169.21 (November 13, 2025) to $337.97 (November 13, 2026), +99.73%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $337.97 |
| October 30, 2026 | $359.41 |
| September 30, 2026 | $295.01 |
| August 31, 2026 | $288.24 |
| July 31, 2026 | $232.51 |
| June 30, 2026 | $226.79 |
| May 29, 2026 | $180.71 |
| April 30, 2026 | $166.97 |
| March 31, 2026 | $172.50 |
| February 27, 2026 | $178.49 |
| January 30, 2026 | $210.48 |
| December 31, 2025 | $199.48 |
| November 28, 2025 | $178.14 |
| November 13, 2025 | $169.21 |
At a glance
The company
Provides drug discovery, safety testing and research models, plus contract manufacturing services for pharma and biotech
Latest results
Quarter to September 30, 2026 · EPS $3.09 (estimate $2.97)
TickerLandia's take on Charles River Laboratories International
- Pricier than similar companies: trailing 12-month P/E 367 vs 38 (+873%) in a group of 9.
- Strong point: Market momentum (98/100 in its group). Weak point: Earnings stability (19/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.97% from the 52-week high
Analysts · 17 analysts
Average target$350.57+3.73% vs. price
Buy 14 · Hold 2 · Sell 1 · Buy
TickerLandia Fingerprint: Charles River Laboratories International
Compared with similar companies: very strong momentum and very low earnings stability.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh64
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 367.4 98 Forward P/E 26.1 70 EV/EBITDA 20.8 50 Price/book 5.01 60 Price/sales 4.07 43 Profitabilitylow26
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 35.1% 31 Net margin 1.0% 17 ROE 1.3% 17 ROA 4.7% 31 Operating margin 14.3% 31 Earnings stabilityvery low19
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 7.3% 20 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 19 Growthaverage46
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +523.60% 98 Revenue growth (year over year) −2.20% 13 Average revenue growth (3 years) +0.33% 28 Financial strengthlow29
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.87 24 Interest coverage 4.65 25 Current ratio 1.41 35 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.76 30 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong98
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +104.31% 100 Relative strength (3 months) +23.93% 95 1-year return +99.73% 98 Distance from 200-day average +48.42% 99 Riskhigh70
How much the price swings.
Metric Value Position in group Beta (1 year) 1.29 73 Volatility (60 days) 48.1% 74 Maximum drawdown (12 months) 33.9% 62
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Charles River Laboratories International is pricier than similar companies
Charles River Laboratories International's P/E (trailing 12 months): 367.4, +873% against the median of a group of 9 similar companies (37.7).
Compared with 9 similar companies
| Metric | Charles River Laboratories International | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 367.4 | High | |
| Forward P/E | 26.1 | Middle | |
| Operating margin | 14.3% | Middle | |
| ROE | 1.3% | Low | |
| Debt/equity | 0.87 | High |
Grey band: the middle half of the group; tick: the median; dot: Charles River Laboratories International. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$982.73M
Latest quarter · Q3 2026
Net income
$333.07M
Latest quarter · Q3 2026
Quarterly net margin
33.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $16.19B
- P/E
- 367.4
- EPS
- $0.92
- Volume
- 823.14K
- Daily trading
- €403.88M
- Dividend yield
- 0.00%
How Charles River Laboratories International is changing
All resultsRevenue grew 6.5% a year on average over the last 5 years
Operating margin fell from 16.4% to 0.6%
Profitable in 4 of 5 fiscal years
Returns
Charles River Laboratories International returns
$1,000 invested in Charles River Laboratories International 5 years ago, on November 15, 2021, would be worth $879 today: −12.11% in total, −2.55% per year. This is the price return only: dividends are excluded.
| Period | Charles River Laboratories International | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +13.03% | −3.12% | $1,130 |
| 6 months | +107.53% | +1.58% | $2,075 |
| Year to date | +69.43% | +10.46% | $1,694 |
| 1 year | +99.73% | +12.23% | $1,997 |
| 3 years | +98.77% | +71.41% | $1,988 |
| 5 years | −12.11% | +61.48% | $879 |
| 10 years | +350.27% | +249.40% | $4,503 |
Over the last 6 months it has done better than 99% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Charles River Laboratories International: technical analysis
Charles River Laboratories International is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 26.3% below its all-time closing high ($458.30, September 24, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 52
- Between 30 and 70
- vs 200-session average
- +48.42%
Support and resistance
Price areas where Charles River Laboratories International has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$337.97
- Support$232.94−31.08%4 touches, last on July 10, 2026
- Support$215.89−36.12%2 touches, last on July 21, 2026
- Support$193.07−42.87%5 touches, last on June 10, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 1.29
- Volatility (60 sessions, annualised)
- 48.1%
- Largest fall in the last year
- −33.88%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Charles River Laboratories International: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Charles River Laboratories International has been July: +5.09% on average, positive in 17 years out of 27. The weakest has been April: −2.10% on average, positive in 10 years out of 26. November, the current month, has been positive in 13 years out of 26 (−0.60% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.97% | +3.86% | 17 of 26 |
| February | +0.89% | +0.88% | 16 of 26 |
| March | +0.27% | +1.80% | 19 of 26 |
| April | −2.10% | −1.66% | 10 of 26 |
| May | +4.61% | +2.17% | 17 of 26 |
| June | +2.77% | +0.81% | 14 of 26 |
| July | +5.09% | +3.88% | 17 of 27 |
| August | +0.49% | −0.64% | 13 of 27 |
| September | +0.20% | +0.16% | 14 of 27 |
| October | −0.83% | +0.32% | 14 of 27 |
| November | −0.60% | +0.28% | 13 of 26 |
| December | +3.73% | +4.19% | 18 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Charles River Laboratories International and its competitors
With 18,300 employees, Charles River Laboratories International, Inc. runs drug discovery, non-clinical development and safety testing services for pharmaceutical and biotechnology companies and for researchers. Its research models unit breeds and sells purpose-bred rats and mice, along with genetically engineered models, insourcing solutions, research animal diagnostics and cell therapy development. Its discovery and safety assessment unit tests novel drugs, oligonucleotides, biotherapeutics and antibodies through toxicology, pathology, bioanalysis and pharmacokinetics work, plus vivarium space.
- Headquarters
- Wilmington, United States
- Employees
- 18,300
- Founded
- 1947
- Chief executive
- Birgit Girshick
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Charles River Laboratories InternationalCRL | $16.19B | 14.3% | 367.4 | +107.53% |
| RevvityRVTY | $17.84B | 16.3% | 70.5 | +62.50% |
| ICON PublicICLR | $14.58B | 2.7% | 77.9 | +65.83% |
| Medpace HoldingsMEDP | $19.12B | 21.4% | 38.0 | +54.32% |
| Guardant HealthGH | $20.52B | -39.4% | — | +54.06% |
| Quest DiagnosticsDGX | $28.56B | 14.9% | 25.9 | +36.02% |
Same industry or related industries, similar size. Compare Charles River Laboratories International with its competitors · Full profile
More on Charles River Laboratories International
- Charles River Laboratories International revenue and financials
- Charles River Laboratories International valuation
- Charles River Laboratories International stock return
- Charles River Laboratories International employees, headquarters and business
